0

Anti-inflammatory Therapeutics Market by Application, Drug Class, and Geography - Forecast and Analysis 2023-2027

  • Published: Dec 2022
  • Pages: 167
  • SKU: IRTNTR41324
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The anti-inflammatory therapeutics market is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The size of the market is forecast to increase by USD 39.32 billion. The growth of the market depends on serval factors, including the increase in off-label use, the unmet need for safer biologics for RA, and the availability of improved diagnostic modalities.

This report extensively covers market segmentation by application (RA, psoriasis, and MS), drug class (anti-inflammatory biologicals, corticosteroids, and NSAIDs), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Anti-inflammatory Therapeutics Market During the Forecast Period?

Anti-inflammatory Therapeutics Market Size

To learn more about this report, Download Report Sample

Parent Market Analysis

Technavio categorizes the global anti-inflammatory therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in research and development or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Anti-inflammatory Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

The unmet need for safer biologics for RA is notably driving the market growth, although factors such as the loss of patents may impede market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Anti-inflammatory Therapeutics Market Driver

The unmet need for safer biologics for RA is notably driving market growth. The use of biologics for the treatment of RA raises safety concerns among rheumatologists. Biologics are immunosuppressive in nature and target parts of the immune system that drive inflammation. Abatacept acts by blocking the communication between inflammatory T-cells; anakinra hampers the protein interleukin-1, which is responsible for inflammation; rituximab destroys white blood cells that cause inflammation; and tocilizumab targets interleukin-6, an immune system protein that causes inflammation. Biologics can cause many side effects because of their immune-modifying actions. 

Although the safety of biologics is established in clinical trials, the safety data is limited to a small number of patients enrolled in trials. In addition, the clinical trials were of short duration. There is limited data available on safety issues that might arise during the long-term use of biologics. The use of TNF-alpha inhibitors has been associated with tuberculosis, and Salmonella infections, such as typhoid and listeria infections. Risks of malignancies were also high in patients undergoing TNF-alpha inhibitor treatment. Hence, the abovementioned factors are expected to drive the growth of the global market during the forecast period.

Significant Anti-inflammatory Therapeutics Market Trend

The use of gene therapy for RA treatment is a major trend in the focused market. Chemical and biological molecules that are used to treat RA have certain limitations. Chemical or synthetic drugs can target normal physiological processes of the body and may have non-specific effects that may be harmful to patients. Similarly, although biologics exhibit site-specific action, they have a shorter half-life in the body and are expensive.

Biologics, such as monoclonal antibodies, have been reported to show immunogenicity. To overcome the limitations associated with conventional therapy, gene therapy has been introduced in the market. A phase I clinical trial was conducted in which a therapeutic gene encoding the IL-1 receptor antagonist was successfully transferred and expressed. This IL-1 receptor antagonist was able to reduce the disease in animal models. Such studies tend to encourage the use of gene therapy as an intervention for the treatment of RA. Hence, the abovementioned factors are expected to fuel the growth of the global market during the forecast period.

Major Anti-inflammatory Therapeutics Challenge

Loss of patents is a major challenge impeding market growth. The global market is currently witnessing the loss of patents on major drugs. The loss of patent protection has led to the entry of generic drugs into the global market, which is available at lower prices than branded drugs. The entry of generic drug manufacturers into the market has propelled the major vendors to provide heavy rebates on their existing products, which, in turn, decreases their market share. The monetary loss to these vendors is subjected to generic erosion.

In addition, the Patient Protection and Affordable Care Act, implemented under the Biologics Price Competition and Innovation Act in the US, promote the approval of biosimilars in the US and allows generic drug manufacturers to refer data from already approved biological drugs. Such government proposals enacted under the law are likely to increase the competition in the market. For instance, HUMIRA accounted for approximately 61% of AbbVie's total revenue in 2021. The drug has already lost its patent rights in the US. Therefore, AbbVie competitors, such as Amgen, have applied to the EMA and the US FDA to grant marketing approval for HUMIRA biosimilar.

To remain competitive and prevent generic erosion, AbbVie must launch new product launches and initiate new indications or brand extensions for its existing products, such as HUMIRA. The new product must generate sufficient revenue that can cover the cost spent on research and development and replace the revenues of profitable products that are likely to be launched by the competitors. Hence, such factors are expected to hinder the growth of the global market during the forecast period.

Key Anti-inflammatory Therapeutics Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Anti-inflammatory Therapeutics Market Share by Geography

Global Anti-inflammatory Therapeutics Market Customer Landscape

Who are the Major Anti-inflammatory Therapeutics Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

GlaxoSmithKline Plc - The company operates under multiple segments including pharmaceuticals, and vaccines among others with a high focus on pharmaceuticals.? The company under this segment?offers a broad portfolio of innovative and established medicines in respiratory, HIV, immune inflammation, and oncology. The company's key offerings include anti-inflammatory therapeutics with the latest developments.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AbbVie Inc.
  • Alvogen Iceland ehf
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd
  • Ferring BV
  • Johnson and Johnson
  • Lupin Ltd.
  • Mylan N.V

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Anti-inflammatory Therapeutics Market?

The market share growth by the RA segment will be significant during the forecast period. RA is an autoimmune and inflammatory disease characterized by joint pain. The disease arises when the body's immune system is triggered against the healthy cells in the body by mistake and, hence, called autoimmune. This causes inflammation in the affected part of the body.

Anti-inflammatory Therapeutics Market Size

Get a glance at the market contribution of various segments Request a PDF Sample

The RA segment shows a gradual increase in the market share of USD 45.16 billion in 2017 and continued to grow until 2021 Arthritis is a leading cause of disability, which causes aching, pain, stiffness, and swelling of the joints. The most common types are osteoarthritis, rheumatoid arthritis, lupus, gout, and fibromyalgia. By 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis. Arthritis can be a hurdle to physical activity due to miserable joint pain, and inactivity associated with arthritis can lead to conditions such as cardiovascular disease, diabetes, and obesity. Hence, such a high prevalence and incidence rate of arthritis (of which rheumatoid arthritis is one of the most common types) will increase the demand for anti-inflammatory drugs, thus driving the market growth. The RA segment of the global market is expected to grow at a moderate pace during the forecast period. 

Which are the Key Regions for the Anti-inflammatory Therapeutics Market?

Anti-inflammatory Therapeutics Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market in North America dominated the global market in 2022. The growth of the market in this region is primarily driven by the sales of approved drugs for the treatment of conditions causing inflammation and the increasing prevalence of several associated risk factors for the condition. The market is growing due to the high prevalence of Immunomodulatory imide drug (IMID) and autoimmune diseases, which, in turn, increases the demand for such therapeutics. Furthermore, the CDC estimated that by 2040, about 78.00 million US adults are projected to have doctor-diagnosed arthritis. Hence, such a high prevalence of arthritis increases the risk of inflamed conditions, which is expected to drive the growth of the market in North America during the forecast period.

Although the US has many approved corticosteroids for the treatment of the condition and advanced diagnostic infrastructure, the high cost of these drugs is a potential challenge to the market. To mitigate this challenge, various vendors are offering patient assistance programs. Furthermore, vendors such as AbbVie are striving to develop newer biologics that are based on novel mechanisms of action. Such initiatives by the vendors are likely to drive market growth in this region. However, patent loss is a major hurdle that is expected to hinder the market growth during the forecast period.

The outbreak of COVID-19 in 2020 severely impacted the market in North America. However, the lifting of lockdowns, followed by the rescheduling of patient visits to clinics and the adoption of contactless delivery of such therapeutics, was increased in 2021 and 2022; and it is expected to boost the growth of the regional market during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by Application (RA, Psoriasis, and MS), Drug Class (Anti-inflammatory biologicals, Corticosteroids, and NSAIDs), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

  • Application Outlook (USD Billion, 2017 - 2027)
    • RA
    • Psoriasis
    • MS
  • Drug Class Outlook (USD Billion, 2017 - 2027)
    • Anti-inflammatory biologicals
    • Corticosteroids
    • NSAIDs
  • Region Outlook (USD Billion, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Thailand
      • Vietnam
      • Indonesia
      • Others
    • Rest of World
      • Saudi Arabia
      • South Africa
      • Brazil
      • Chile
      • Argentina
      • Others

Anti-inflammatory Therapeutics Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.7%

Market growth 2023-2027

USD 39.32 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

5.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 45%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ferring BV, GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Sanofi SA

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Anti-inflammatory Therapeutics Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the anti-inflammatory therapeutics market  between 2023 and 2027
  • Precise estimation of the anti-inflammatory therapeutics market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of anti-inflammatory therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global anti-inflammatory therapeutics market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global anti-inflammatory therapeutics market 2017 - 2021 ($ billion)
    • 4.2 Application Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ billion)
    • 4.3 Drug class Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Drug class Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 RA - Market size and forecast 2022-2027
      • Exhibit 34: Chart on RA - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on RA - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on RA - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on RA - Year-over-year growth 2022-2027 (%)
    • 6.4 Psoriasis - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Psoriasis - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on Psoriasis - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on Psoriasis - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Psoriasis - Year-over-year growth 2022-2027 (%)
    • 6.5 MS - Market size and forecast 2022-2027
      • Exhibit 42: Chart on MS - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on MS - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on MS - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on MS - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Application
      • Exhibit 46: Market opportunity by Application ($ billion)

    7 Market Segmentation by Drug Class

    • 7.1 Market segments
      • Exhibit 47: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Drug Class - Market share 2022-2027 (%)
    • 7.2 Comparison by Drug Class
      • Exhibit 49: Chart on Comparison by Drug Class
      • Exhibit 50: Data Table on Comparison by Drug Class
    • 7.3 Anti-inflammatory biologicals - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Anti-inflammatory biologicals - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 52: Data Table on Anti-inflammatory biologicals - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 53: Chart on Anti-inflammatory biologicals - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Anti-inflammatory biologicals - Year-over-year growth 2022-2027 (%)
    • 7.4 Corticosteroids - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Corticosteroids - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 56: Data Table on Corticosteroids - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 57: Chart on Corticosteroids - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Corticosteroids - Year-over-year growth 2022-2027 (%)
    • 7.5 NSAIDs - Market size and forecast 2022-2027
      • Exhibit 59: Chart on NSAIDs - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 60: Data Table on NSAIDs - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Chart on NSAIDs - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on NSAIDs - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Drug Class
      • Exhibit 63: Market opportunity by Drug Class ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 65: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 67: Chart on Geographic comparison
      • Exhibit 68: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 98: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 99: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 105: Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 106: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 108: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 109: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 110: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 111: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 112: AbbVie Inc. - Overview
              • Exhibit 113: AbbVie Inc. - Product / Service
              • Exhibit 114: AbbVie Inc. - Key news
              • Exhibit 115: AbbVie Inc. - Key offerings
            • 12.4 Alvogen Iceland ehf
              • Exhibit 116: Alvogen Iceland ehf - Overview
              • Exhibit 117: Alvogen Iceland ehf - Product / Service
              • Exhibit 118: Alvogen Iceland ehf - Key offerings
            • 12.5 Amgen Inc.
              • Exhibit 119: Amgen Inc. - Overview
              • Exhibit 120: Amgen Inc. - Product / Service
              • Exhibit 121: Amgen Inc. - Key offerings
            • 12.6 Amneal Pharmaceuticals Inc.
              • Exhibit 122: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 123: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 124: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 125: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 126: Amneal Pharmaceuticals Inc. - Segment focus
            • 12.7 Bayer AG
              • Exhibit 127: Bayer AG - Overview
              • Exhibit 128: Bayer AG - Business segments
              • Exhibit 129: Bayer AG - Key news
              • Exhibit 130: Bayer AG - Key offerings
              • Exhibit 131: Bayer AG - Segment focus
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 132: Bristol Myers Squibb Co. - Overview
              • Exhibit 133: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 134: Bristol Myers Squibb Co. - Key news
              • Exhibit 135: Bristol Myers Squibb Co. - Key offerings
            • 12.9 Eli Lilly and Co.
              • Exhibit 136: Eli Lilly and Co. - Overview
              • Exhibit 137: Eli Lilly and Co. - Product / Service
              • Exhibit 138: Eli Lilly and Co. - Key offerings
            • 12.10 F. Hoffmann-La Roche Ltd
              • Exhibit 139: F. Hoffmann-La Roche Ltd - Overview
              • Exhibit 140: F. Hoffmann-La Roche Ltd - Product / Service
              • Exhibit 141: F. Hoffmann-La Roche Ltd - Key offerings
            • 12.11 Ferring BV
              • Exhibit 142: Ferring BV - Overview
              • Exhibit 143: Ferring BV - Product / Service
              • Exhibit 144: Ferring BV - Key offerings
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 145: GlaxoSmithKline Plc - Overview
              • Exhibit 146: GlaxoSmithKline Plc - Business segments
              • Exhibit 147: GlaxoSmithKline Plc - Key offerings
              • Exhibit 148: GlaxoSmithKline Plc - Segment focus
            • 12.13 Johnson and Johnson
              • Exhibit 149: Johnson and Johnson - Overview
              • Exhibit 150: Johnson and Johnson - Business segments
              • Exhibit 151: Johnson and Johnson - Key news
              • Exhibit 152: Johnson and Johnson - Key offerings
              • Exhibit 153: Johnson and Johnson - Segment focus
            • 12.14 Mylan N.V
              • Exhibit 154: Mylan N.V - Overview
              • Exhibit 155: Mylan N.V - Product / Service
              • Exhibit 156: Mylan N.V - Key offerings
            • 12.15 Novartis AG
              • Exhibit 157: Novartis AG - Overview
              • Exhibit 158: Novartis AG - Business segments
              • Exhibit 159: Novartis AG - Key offerings
              • Exhibit 160: Novartis AG - Segment focus
            • 12.16 Pfizer Inc.
              • Exhibit 161: Pfizer Inc. - Overview
              • Exhibit 162: Pfizer Inc. - Product / Service
              • Exhibit 163: Pfizer Inc. - Key news
              • Exhibit 164: Pfizer Inc. - Key offerings
            • 12.17 Teva Pharmaceutical Industries Ltd.
              • Exhibit 165: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 166: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 169: Teva Pharmaceutical Industries Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 170: Inclusions checklist
                • Exhibit 171: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 172: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 173: Research methodology
                • Exhibit 174: Validation techniques employed for market sizing
                • Exhibit 175: Information sources
              • 13.5 List of abbreviations
                • Exhibit 176: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Anti-inflammatory Therapeutics market growth will increase by $39.32 billion during 2023-2027.
              The anti-inflammatory therapeutics market is expected to grow at a CAGR of 6.7% during 2023-2027.
              Technavio has segmented the anti-inflammatory therapeutics market by application (RA, Psoriasis, and MS) ,drug class (Anti-inflammatory biologicals, Corticosteroids, NSAIDs, ROW, and North America) , and geography (North America, Europe, Asia, and Rest of World (ROW)).
              AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ferring BV, GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi SA are a few of the key vendors in the anti-inflammatory therapeutics market.
              North America will register the highest growth rate of 44.99% among the other regions. Therefore, the anti-inflammatory therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the anti-inflammatory therapeutics market growth are:
              • Increase in off-label use
              • Emergence of novel anti-inflammatory drugs
              The anti-inflammatory therapeutics market vendors should focus on grabbing business opportunities from the ra segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>